BioSpace News Archive

The shifting regulatory landscape and growing demand for quicker approval processes are positively influencing the progress of the global medical device regulatory affairs market.

Increasing cases of blood vessel inflammatory diseases is the key factor responsible for the growth of the global leukocytoclastic vasculitis market.

RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat COVID-19 induced respiratory disorders, announced the appointment of Taneli Jouhikainen, M.D., MBA, to the newly created position of Chief Operating Officer, effective June 1, 2021.

Publication also documents the ability to deliver targeted thrombolytic medication via IRRAflow’s recurring irrigation for the first time in peer-reviewed scientific literature

Sugemalimab is the first PD(L)1 monoclonal antibody to demonstrate a progression-free survival benefit in Stage III non-small cell lung cancer (NSCLC) patients after treatment with either concurrent or sequential chemoradiotherapy

Zhongchao Inc., a healthcare services company offering online healthcare information, professional training and educational services, announced the launch of the patient management service focusing on the professional field of tumor and rare disease operated through its subsidiary Shanghai Zhongxin Medical Technology Co., Ltd..

Transparency Market Research in its new report predicts that the global metabolomics market will undergo a tremendous transformation in the near future.

Increasing approvals and government initiatives are encouraging biosimilar drugs production and are creating opportunities for growth in the fusion protein biosimilar market

NEC Corporation announced the development of an AI technology for supporting doctors to detect neoplasia in Barrett’s esophagus during endoscopic procedures.

Immunovia AB announces that Patrik Dahlen, CEO of Immunovia, has purchased 6,860 shares for approximately SEK 675,000 over the stock exchange.